Ticker > Company >

Indoco Remedies share price

Indoco Remedies Ltd.

NSE: INDOCO BSE: 532612 SECTOR: Pharmaceuticals & Drugs  68.26 K   137   18

310.30
+33.50 (12.10%)
BSE: 11 Sep 04:01 PM

Price Summary

Today's High

₹ 332.15

Today's Low

₹ 279.7

52 Week High

₹ 385.5

52 Week Low

₹ 190

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

2862.45 Cr.

Enterprise Value

3588.41 Cr.

No. of Shares

9.22 Cr.

P/E

0

P/B

2.68

Face Value

₹ 2

Div. Yield

0.06 %

Book Value (TTM)

₹  115.94

CASH

12.03 Cr.

DEBT

737.99 Cr.

Promoter Holding

58.9 %

EPS (TTM)

₹  -5.61

Sales Growth

-15.22%

ROE

-0.79 %

ROCE

2.84%

Profit Growth

-107.49 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Indoco Remedies Ltd.

SPADE SURGE-RADIUS WARREN WARREN-EXCEL SPERA

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-15.22%
3 Year-0.47%
5 Year6.54%

Profit Growth

1 Year-107.49%
3 Year-138.38%
5 Year-181.53%

ROE%

1 Year-0.79%
3 Year8.24%
5 Year11.19%

ROCE %

1 Year2.84%
3 Year11.05%
5 Year14.41%

Debt/Equity

0.6724

Price to Cash Flow

31.54

Interest Cover Ratio

0.8698

CFO/PAT (5 Yr. Avg.)

1.41494382391583

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 58.90 0.00
Mar 2025 58.90 0.00
Dec 2024 58.80 0.00
Sep 2024 58.75 0.00
Jun 2024 58.75 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 65.391 days.
  • The company has a high promoter holding of 58.9%.

 Limitations

  • The company has shown a poor profit growth of -138.378811247785% for the Past 3 years.
  • The company has shown a poor revenue growth of -0.468227062666271% for the Past 3 years.
  • Company has low Interest coverage ratio of 0.8698.
  • Company has contingent liabilities of 392.1208 Cr.
  • The company is trading at a high EV/EBITDA of 32.0852.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 401.43 396.53 372.98 347.25 392.53
Total Expenditure 349.86 343.66 352.84 343.79 377.7
Operating Profit 51.57 52.87 20.14 3.46 14.83
Other Income 3.52 4.2 4.26 6.5 5.58
Interest 11.88 14.77 14 15.98 23.61
Depreciation 23.7 24.92 24.75 24.88 25.2
Exceptional Items 0 0 0.99 0 0
Profit Before Tax 19.51 17.38 -13.36 -30.9 -28.4
Tax 4.56 4.59 -3.13 -4.66 -0.34
Profit After Tax 14.95 12.79 -10.23 -26.24 -28.06
Adjusted EPS (Rs) 1.62 1.39 -1.11 -2.84 -3.04

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 1240.3 1539.72 1666.69 1790.81 1518.19
Total Expenditure 1022.67 1213.81 1381.85 1540.71 1390.16
Operating Profit 217.63 325.91 284.84 250.1 128.03
Other Income 9.05 6.71 2.62 17.38 18.48
Interest 22.22 17.43 25.27 37.8 56.63
Depreciation 73.12 78.95 70.6 87.98 98.25
Exceptional Items 0 0 0 11.53 0.99
Profit Before Tax 131.35 236.23 191.59 153.23 -7.38
Tax 38.96 81.71 50.23 36.58 1.36
Net Profit 92.39 154.52 141.36 116.64 -8.74
Adjusted EPS (Rs.) 10.03 16.77 15.34 12.65 -0.95

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 18.43 18.43 18.43 18.44 18.45
Total Reserves 750.5 885.87 1008.59 1108.18 1084.91
Borrowings 96.94 95.88 143.5 203.6 336.89
Other N/C liabilities 61.36 60.68 61.91 68.14 65.9
Current liabilities 408.54 519.93 483.21 595.03 695.01
Total Liabilities 1335.76 1580.8 1715.64 1993.38 2201.16
Assets
Net Block 569.91 554.98 661.46 732.34 754.38
Capital WIP 25.12 52.82 54.36 92.5 181.37
Intangible WIP 42.98 68.72 58.21 21.94 44.42
Investments 2.45 2.46 18.9 51.96 51.96
Loans & Advances 71.29 33.68 52.03 154.87 207.26
Other N/C Assets 2.05 2.13 2.25 6.78 6.3
Current Assets 621.95 866.01 868.44 932.99 955.47
Total Assets 1335.76 1580.8 1715.64 1993.38 2201.16
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 131.35 236.23 191.59 141.7 -8.37
Adjustment 109.71 87.12 120.88 130.08 147.22
Changes in Assets & Liabilities -139.14 -108.81 -72.29 -77.42 -32.49
Tax Paid -19.75 -40.99 -61.38 -29.1 -16.6
Operating Cash Flow 82.17 173.55 178.79 176.78 90.77
Investing Cash Flow -66.7 -121.41 -208.51 -301.7 -259.79
Financing Cash Flow -29.83 -44.37 22.81 122.4 168.62
Net Cash Flow -14.35 7.77 -6.91 -2.52 -0.41

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 58.75 58.75 58.80 58.90 58.90
kare aruna suresh 5.20 5.20 5.20 5.20 5.20
kare suresh govind 4.40 4.40 4.40 4.40 4.40
madhura suresh kare 5.65 5.65 5.65 5.68 5.68
mahika milind panandikar 0.01 0.01 0.01 0.01 0.01
megh milind panandikar 0.01 0.01 0.01 0.01 0.01
milind s panandikar 0.01 0.01 0.01 0.01 0.01
panandikar aditi milind 6.08 6.08 6.13 6.14 6.14
pooja rajendra pai - - - 0.01 0.01
pratima ajit vaidya 0.03 0.03 0.03 0.03 0.03
rohan anup ramani 0.01 0.01 0.01 0.01 0.01
shanteri investment pvt l... 17.11 17.11 17.11 17.19 17.19
sharda ramnath kare 0.04 0.04 0.04 0.04 0.04
spa holdings pvt ltd 19.89 19.89 19.89 19.88 19.88
suresh govind kare huf (k... - 0.30 0.30 0.30 0.30
sudha m pai 0.01 0.01 0.01 - -
suresh govind kare (huf) ... 0.30 - - - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 41.25 41.25 41.20 41.10 41.10
dsp healthcare fund 2.27 2.52 3.91 3.98 4.01
franklin india smaller co... 1.48 1.48 1.48 2.20 2.20
hdfc value fund - - - 1.67 1.67
independent director - 0.01 - - 0.01
investor education and pr... 0.11 0.11 0.18 - 0.18
llp 0.07 0.09 0.12 0.15 0.12
mangeshi investment priva... 1.27 1.27 - 1.27 1.27
nippon life india trustee... - - - - 4.80
quant mutual fund -quant ... - - - - 4.55
tata india pharma & healt... - - 1.32 1.32 1.32
investor education and pr... - - - 0.18 -
nippon life india trustee... 4.97 4.97 4.81 4.80 -
quant mutual fund - quant... 4.56 4.56 4.56 4.55 -
hdfc trustee company ltd.... - 1.67 1.67 - -
mangeshi investmentprivat... - - 1.27 - -
icici prudential smallcap... 1.79 1.14 - - -
hdfc trustee company ltd ... 1.45 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit ICRA
Credit ICRA
Credit ICRA
TYPE AGENCY Link
TYPE AGENCY Link
Research Ventura
Research HDFC Securities
Research Nirmal Bang
Research Prabhudas Lilladhar

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q3FY25
Concall Q3FY24
Concall Q3FY22
Concall Q3FY21
Concall Q2FY24
Concall Q2FY21
Concall Q1FY25
Concall Q1FY25
Concall Q1FY24
Concall Q1FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q3FY22

Company News

Indoco Remedies Stock Price Analysis and Quick Research Report. Is Indoco Remedies an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Indoco Remedies. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Indoco Remedies has a PE ratio of -55.0206817857652 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Indoco Remedies has ROA of -0.4165% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Indoco Remedies has a Current ratio of 1.3748.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Indoco Remedies has a ROE of -0.7867%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Indoco Remedies has a Debt to Equity ratio of 0.6724 which means that the company has low proportion of debt in its capital.

  • Sales growth: Indoco Remedies has reported revenue growth of -15.2232% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Indoco Remedies for the current financial year is 8.43318863237338%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Indoco Remedies is Rs 0.2 and the yield is 0.0647%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Indoco Remedies is Rs -5.6088. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Indoco Remedies in Ticker for free. Also, one can get the intrinsic value of Indoco Remedies by using Valuation Calculators, which are available with a Finology ONE subscription. 

Indoco Remedies FAQs

Q1. What is Indoco Remedies share price today?
Ans: The current share price of Indoco Remedies is Rs 308.6.

Q2. What is the market capitalisation of Indoco Remedies?
Ans: Indoco Remedies has a market capitalisation of Rs 2846.7703483 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Indoco Remedies?
Ans: The PE ratio of Indoco Remedies is -55.0206817857652 and the P/B ratio of Indoco Remedies is 2.66162745667956, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Indoco Remedies share?
Ans: The 52-week high share price of Indoco Remedies is Rs 383, and the 52-week low share price of Indoco Remedies is Rs 190.

Q5. Does Indoco Remedies pay dividends?
Ans: Currently, Indoco Remedies pays dividends. Dividend yield of Indoco Remedies is around 0.0647%.

Q6. What are the face value and book value of Indoco Remedies shares?
Ans: The face value of Indoco Remedies shares is Rs 2, while the book value per share of Indoco Remedies is around Rs 115.9441. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Indoco Remedies?
Ans: Indoco Remedies has a total debt of Rs 737.9905 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Indoco Remedies?
Ans: The ROE of Indoco Remedies is -0.7867% and ROCE of Indoco Remedies is 2.8433%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Indoco Remedies a good buy for the long term?
Ans: The Indoco Remedies long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Indoco Remedies undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Indoco Remedies appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Indoco Remedies’s financials?
Ans: You can review Indoco Remedies’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Indoco Remedies
X